Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia
Pinkal Desai(NewYork–Presbyterian Hospital), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Wendy Stock(University of Chicago), Ramkumar Mandalam(Cellerant Therapeutics (United States)), Matthew J. Wieduwilt(Atrium Health Wake Forest Baptist), Olga Frankfurt, Alicia Wong(Broad Institute), J. Martin Brown(Palo Alto University), Patrick J. Stiff(Loyola University Medical Center), Suman Kambhampati(Veterans Health Administration), Lois Kellerman(Cellerant Therapeutics (United States)), James M. Foran(Memorial Sloan Kettering Cancer Center), Irum Khan(University of Illinois Chicago), Gary J. Schiller(Fred Hutch Cancer Center), Saar Gill(Parker Institute for Cancer Immunotherapy), John M. Pagel(University of Washington), Iskra Pusic(Washington University in St. Louis), Delong Liu(Westchester Medical Center), Lawrence E. Morris(Northside Hospital), Charalambos Andreadis(University of California, San Francisco), Celalettin Üstün(Rush University Medical Center), Swapna Panuganti(Cellerant Therapeutics (United States)), John Lister(Allegheny Health Network), Rodney Van Syoc(Cellerant Therapeutics (United States)), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), John Edwards(Indiana Cancer Consortium), Camille N. Abboud(Washington University in St. Louis), Melham Solh(Northside Hospital), Luke P. Akard(Franciscan Health Indianapolis), Richard D. Mamelok(Johnson & Johnson (United States)), Jack W. Hsu(University of Florida Health), Martin S. Tallman(Memorial Sloan Kettering Cancer Center)
Cited by 21
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k